Effective December 28, 2021, ZIOPHARM Oncology, Inc. as borrower, entered into a First Amendment to the Loan and Security Agreement dated August 6, 2021, by and among the Company, the lenders party thereto and Silicon Valley Bank, as administrative agent and collateral agent The Amendment principally makes the below modifications.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6149 USD | -9.31% |
|
-3.55% | -42.02% |
06-10 | BioSig Technologies Appoints Ferdinand Groenewald as Interim CFO | MT |
05-15 | Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-42.02% | 10.86M | |
+20.17% | 127B | |
+24.67% | 117B | |
+25.44% | 27.67B | |
-17.74% | 20.33B | |
-15.17% | 16.79B | |
-15.21% | 15.63B | |
+11.91% | 14.84B | |
-47.10% | 14.65B | |
+54.50% | 14.43B |
- Stock Market
- Equities
- TCRT Stock
- News Alaunos Therapeutics, Inc.
- ZIOPHARM Oncology, Inc. Enters into First Amendment to the Loan and Security Agreement